[The best of arrhythmias in 2002].
In the era of evidence based medicine the year 2002 will be remembered principally for having brought the results of two large trials in areas of daily preoccupation for rhythmologists: those of atrial fibrillation and of prevention of rhythmic sudden death. The Atrial Fibrillation Following Investigation of Rhythm Management (AFFIRM) study compared strategies for controlling frequency and rhythm in atrial fibrillation for subjects aged over 65 years or having at least one risk factor for cerebral vascular accident. In an unexpected fashion, although in accordance with other recent results, the two strategies are equivalent in terms of mortality. It also underlined the necessity of continuing anticoagulation with an INR > 2. even when it is proposed to maintain the rhythm. In the matter of primary prevention of sudden coronary death, the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) had the originality of evaluating patients with no other risk factor than a severe alteration in left ventricular ejection fraction (30% Pounds). This "simple" selection of patients at risk allowed a mortality reduction of 30% to be demonstrated by the placement of a ventricular defibrillator, in addition to that brought about by optimal conventional treatment. In the chapter on syncope, the Framingham study delivers information in terms of incidence and long term prognosis, in a non selected population. Even if these results are difficult to compare with those recent studies using notably the inclination test, they remind us of the poor prognosis of cardiac origin syncope and the absence of excess mortality in patients affected by vagal syncope. The significance of these very wide series does not preclude drawing the greatest attention to the work by the Bordeaux team who have been able to provide evidence, in 27 patients with relapsing idiopathic ventricular fibrillation, of the initiator role of extra-systoles originating from the distal Purkinje network. A medium term cure was obtainable by ablation of these extra-systoles. This work of course allows the prospect of application to other types of malign ventricular arrhythmias.
Saoudi
N
N
Service de cardiologie, Centre hospitalier Princesse-Grace, avenue Pasteur 98000 Monaco.
Deharo
J C
JC
D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D011379:Prognosis
D000925:Anticoagulants